Results 181 to 190 of about 67,846 (274)

Dynamic Parameters within the First 72 H of ICU Admission Predict Extubation Failure and 28‐Day Mortality in Severe Pneumonia‐Induced ARDS: A Retrospective Cohort Study

The Clinical Respiratory Journal, Volume 20, Issue 5, May 2026.
Early 72‐h dynamic changes in key physiological and laboratory parameters predict extubation failure and 28‐day mortality in severe pneumonia‐induced ARDS. Extubation failure is strongly associated with increased mortality, highlighting the clinical value of dynamic monitoring for early risk stratification in ICU patients.
Chen Wang, Yalong Liu, Wenqing Xu, Hanhan Hong   +3 more
wiley   +1 more source

Bispecific Dual‐Immune Checkpoint Inhibitor Associated Cutaneous Toxicity: A Report of Lorigerlimab Adverse Skin Reaction in Two Cancer Patients

Journal of Cutaneous Pathology, Volume 53, Issue 5, Page 422-426, May 2026.
ABSTRACT Lorigerlimab is a dual bispecific antibody (BsAb) targeting cytotoxic T‐lymphocyte‐associated protein 4 and programmed cell death protein 1 that is used for treatment of advanced solid cancers such as metastatic castration‐resistant prostate carcinoma.
Niloofar Sina, Fiorinda Muhaj, Volha Lenskaya, Doina Ivan, Victor G. Prieto, Jonathan L. Curry   +5 more
wiley   +1 more source

Efficacy and safety of efgartigimod in very-late-onset myasthenia gravis. [PDF]

Front Immunol
Zhao Y, Qu M, Rong X, Sun X, Wang L, Liu M, Sui J.   +6 more
europepmc   +1 more source

Evaluation of Sustained Disease Control With Nipocalimab Versus Placebo in the Phase 3 Vivacity‐MG3 Study

European Journal of Neurology, Volume 33, Issue 5, May 2026.
In the Vivacity‐MG3 study, clinical response to nipocalimab was assessed using the MG‐ADL and QMG measures. Nipocalimab treatment improves gMG symptoms earlier than placebo and provides sustained disease control over the 24‐week double‐blind period.
Tuan Vu, Said R. Beydoun, Richard J. Nowak, Hans Katzberg, Maria Ait‐Tihyaty, Kavita Gandhi, John J. Sheehan, Sheryl Pease, Ibrahim Turkoz, Bernie Sattin, Zia Choudhry, Sindhu Ramchandren, Carlo Antozzi   +12 more
wiley   +1 more source

Successful prehospital resuscitation of a young female patient with myasthenia gravis experiencing cardiopulmonary arrest due to complete airway obstruction: a case report and review of the literature. [PDF]

J Med Case Rep
Ruan Z, Wang T, Luo W, Xia Y, Zhou X, Tian Y, Li K, Liu Y.   +7 more
europepmc   +1 more source

Myasthenia Gravis [PDF]

Autoimmune Diseases, 2011
Aarli, Johan A., Gilhus, Nils Erik, Lisak, Robert P., Mantegazza, Renato, Suzuki, Shigeaki   +4 more
openaire   +2 more sources

Real‐World Occurrence of Adverse Events Associated With Adjuvant Pembrolizumab Therapy for Renal Cell Carcinoma: A Multicenter Retrospective Study

International Journal of Urology, Volume 33, Issue 5, May 2026.
ABSTRACT Background Pembrolizumab is indicated as adjuvant therapy after nephrectomy in patients with high‐risk renal cell carcinoma (RCC). However, data regarding the occurrence of treatment‐related adverse events (TRAEs) associated with pembrolizumab in real‐world clinical settings in Japanese patients remain limited.
Koji Iinuma, Kohei Nishikawa, Yuta Sano, Kaori Ozawa, Toyohiro Yamada, Tomoki Taniguchi, Keita Nakane, Takahiro Inoue, Shusuke Akamatsu, Takuya Koie   +9 more
wiley   +1 more source

Concurrent Nivolumab-Induced Myocarditis and Myasthenia Gravis: A Case Report. [PDF]

Case Rep Oncol Med
Gupta R, Plumber N, Lee J, Sivasubramanian BP, Kyhan ME, Singh H, Gupta S.   +6 more
europepmc   +1 more source

Myasthenia-Like Presentations Following PD-1 Inhibitors: CD8+ Myositis, Myasthenia, or Both? [PDF]

Cureus
Ucem S, Yunisova G, Bulus E, Lacin S, Oflazer P.   +4 more
europepmc   +1 more source

Early Relapse Frequency as a Potential Predictor of Generalization in Ocular Myasthenia Gravis: A Case Report. [PDF]

Cureus
Terai J, Matsubayashi T, Furuki M, Obayashi M.   +3 more
europepmc   +1 more source